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Abstract
The Hedgehog-GLI signaling pathway is active in a variety of human malignancies and is known to contribute to the growth
and survival of human osteosarcoma cells. In this study, we examined the expression and regulation of GLI transcription
factors in multiple canine osteosarcoma cell lines and analyzed the effects of inhibiting GLI with GANT61, a GLI-specific
inhibitor. Compared with normal canine osteoblasts, real-time PCR showed that GLI1 and GLI2 were highly expressed in two
out of three cell lines and correlated with downstream target gene expression of PTCH1and PAX6. Treatment of canine
osteosarcoma cells with GANT61 resulted in decreased expression of GLI1, GLI2, PTCH1, and PAX6. Furthermore, GANT61
inhibited proliferation and colony formation in all three canine osteosarcoma cell lines. The finding that GLI signaling
activity is present and active in canine osteosarcoma cells suggests that spontaneously arising osteosarcoma in dogs might
serve as a good model for future preclinical testing of GLI inhibitors.
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Introduction
The Hedgehog (Hh) signaling pathway has long been known to
play a critical role in early embryonic development [1]. It is now
known that Hh signaling contributes to tumor growth and
chemoresistance in a variety of human tumors including osteo-
sarcoma (OSA) [2–7]. The Hh signaling pathway is activated upon
the binding of Hh ligand to its twelve transmembrane receptor
patched 1 (PTCH1). This binding relieves inhibition of smooth-
ened (SMO), a seven transmembrane receptor regulated by
PTCH1. Upon activation, SMO enters into the cytoplasm and
activates transcription factors, most notably, the GLI family of
proteins. In mammals, the GLI family of proteins consists of three
family members, GLI1, GLI2, and GLI3 that differentially
regulate downstream Hh pathways. GLI1 and GLI2 are typically
found to induce distinct and overlapping target genes, whereas
GLI3 can additionally serve as a repressor. GLI proteins are
phosphorylated in the presence of fused serine/threonine kinase
[8] and Costal-2 a kinase-like cytoplasmic protein (Cos2) [9].
Activated GLI proteins enter into the nucleus and bind to the
promoter of various cell regulatory genes including GLI itself and
PTCH1. Therefore, a high level of GLI expression is often
indicative of activated Hh signaling.
While canonical Hh signaling is mainly mediated by PTCH1
and SMO, recent data has clearly demonstrated a parallel
existence of non-canonical Hh signaling pathways [10]. The Hh
signaling pathway has been found to play a critical role in many
human cancers including basal cell carcinoma, medulloblastoma,
glioma, colon, breast, lung, pancreas and recently in OSA
[6,7,11]. This pathway mediates cell growth and survival through
activation of pathways associated with transcription factors GLI1
and GLI2 [12,13]. However, GLI2 often acts as a main
transcription factor in the absence of GLI1 [14,15]. Recent
studies have found that human OSA cells have low expression of
GLI1 compared to GLI2 and that GLI2 appears to serve as the
driving transcription factor of Hh signaling thus contributing to
the growth of OSA [7,16]. A separate study also identified GLI2 as
the main transcription factor of Hh signaling in human OSA
growth, and further found that expression of GLI2 correlated with
poor outcome in human patients with OSA [7]. Additional studies
have found that inhibition of SMO in human OSA cell lines and
mouse xenografts can inhibit canonical Hh signaling and may be
an effective therapeutic approach for the treatment of human
OSA [6].
As an alternative to targeting SMO, compounds such as arsenic
trioxide have been found to inhibit GLI transcription factors and
can inhibit growth of sarcoma or OSA cells that express GLI
[17,18]. Recently, two small molecules have been identified,
GANT61 and GANT58, which specifically inhibit GLI proteins
and serve to prevent their interaction with DNA. Subsequently it
has been shown that GLI inhibitors can effectively block Hh
signaling and inhibit cancer growth in vitro and in vivo [7,19].
Targeting the Hh signaling pathway at the level of GLI, instead of
at the level of SMO, may represent an attractive approach since it
could potentially inhibit both canonical and non-canonical
mediated up-regulation of this pathway [20].
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Spontaneously occurring OSA in the dog very closely models
the human disease with striking similarities at the clinical and
molecular levels [21–23]. While very little is known about the
contribution of Hh-GLI signaling in spontaneously arising canine
cancers, alterations in this pathway have been implicated in both
canine appendicular and extra-skeletal mammary OSA [24,25].
Based on the importance of Hh-GLI signaling pathways in human
cancers including OSA, we set out to determine whether GLI
signaling is present and active in canine OSA cell lines. We found
that GLI signaling is indeed present and active in multiple canine
OSA cell lines and that GANT61 inhibition at the level of GLI
modulates expression of downstream target genes and reduces
proliferation of canine OSA cells.
Results
Expression of GLI1 and GLI2 in Canine OSA
We first examined the mRNA expression of the transcription
factor GLI1 and found high expression of GLI1 mRNA (transcript)
in 2 out of 3 cell lines (Abrams and D17) relative to osteoblast cells
(Fig.1A). We then checked the expression of GLI2 at the mRNA
level and also found high expression of GLI2 mRNA in both
Abrams and D17 cell lines (Fig.1B). In contrast, Moresco cells
expressed relatively low levels of GLI1 and GLI2 mRNA when
compared to osteoblasts or Abrams and D17 OSA cell lines.
Western blot results confirmed varying expression of GLI1 and
GLI2 proteins in all canine OSA cell lines. (Fig. 2)
Constitutive Expression of GLI target genes in Canine
OSA
We next investigated the mRNA expression of the PTCH1
transmembrane receptor and found high expression of PTCH1
mRNA in Abrams and D17 cell lines compared to canine
osteoblast cells (Fig.1C). As would be expected based on GLI
expression, Moresco cells expressed lower constitutive levels of
PTCH1 than osteoblast, D17, or Abrams cell lines. While little is
known about PAX6 in OSA, it is a homeodomain-transcription
factor I and one of the putative downstream targets of the Hh-GLI
signaling pathway [26]. We therefore examined PAX6 gene
expression and found that PAX6 was highly expressed in Abrams
and D17 OSA cell lines that expressed high constitutive levels of
GLI (Fig.1D).
The GLI inhibitor GANT61 decreases colony formation
and proliferation of canine OSA
To determine the effect of GLI inhibition on colony formation,
we performed clonogenic assays in all three OSA cell lines and
found that colony formation in all cell lines was inhibited by
GANT61 and that D17 cells appeared to be most sensitive
(Fig.3A–3C). To expand on these findings, we performed MTS
assays to better define the time and concentration dependent
effects of GANT61 on canine OSA cell lines (Fig. 3D). Indeed,
while GANT61 inhibited proliferation of all cell lines tested, D17
cells were most sensitive to the anti-proliferative effects of
GANT61.
Expression of GLI1 and GLI2 after GANT61 treatments in
D17 canine OSA cells
In order to further investigate the downstream effects of GLI
inhibition, we initially chose to perform experiments using the D17
cell line because it expressed the highest amount of GLI proteins
among the three canine OSA cell lines. After 96 hrs of GANT61
treatment (12 mM), D17 cells showed a significant reduction of
GLI1 mRNA expression compared to vehicle DMSO treated and
untreated cells (Fig.4A). We also observed a significant decrease in
GLI2 mRNA expression after the same treatment with GANT61
when compared with vehicle DMSO treated and untreated cells
(Fig.4B). Importantly, changes in GLI mRNA expression were
found to correlate with changes at the protein level as determined
by Western blot analyses (Fig. 5).
Expression of GLI downstream target genes after
GANT61 treatment in canine OSA cell
We next wanted to examine whether GANT61 inhibition of
GLI expression led to alterations in downstream target gene
mRNA and protein expression. We found that GANT61
decreased levels of PTCH1 mRNA expression by approximately
60% in D17 cells compared to vehicle DMSO treated and
untreated cells (Fig.4C). Furthermore, expression of one of the
putative downstream target genes of the GLI signaling pathway,
PAX6, showed approximately a 40% decrease in mRNA
expression in canine D17 cells after GANT61 treatment compared
to vehicle DMSO treated and untreated cells (Fig.4D). mRNA
changes correlated with protein expression changes for GLI1,
GLI2, PAX6, and PTCH1 (Fig. 5). Taken together, these data
demonstrate that GLI signaling is active and indeed regulates its
target genes in canine OSA cells.
Expression of GLI1 and GLI2 in Moresco cells after
GANT61 treatment
Because we observed inhibition of proliferation and colony
formation in Moresco cells despite relatively low constitutive
expression of GLI1 and GLI2, we wanted to confirm the effect of
GANT61 on the mRNA expression of GLI1 and GLI2 in Moresco
cells. Despite the lower relative expression of GLI in Moresco cells,
after 96 hrs of exposure to 12 mM of GANT61, we indeed
observed a significant reduction of GLI1 and GLI2 mRNA
expression in Moresco cells (Fig. 6), confirming that even relatively
low constitutive levels of GLI signaling can be inhibited.
Discussion
Dogs with spontaneously arising OSA have been found to be an
excellent model for the study of human OSA and this disease
shares many clinical, genetic, and molecular similarities [21–23].
Recent studies have uncovered an important role for Hh-GLI
signaling in human OSA and inhibition of Hh-GLI signaling has
shown promising results in pre-clinical studies [6,7,16,18,27,28].
However, no such studies have examined whether or not this
pathway is active in canine OSA. We now report that multiple
canine OSA cell lines express varying levels of GLI transcription
factors and that the GLI inhibitor, GANT61, is capable of
regulating GLI signaling and cell proliferation in canine OSA cells.
GLI transcription factors represent the primary mediators of Hh
signaling. Aberrant Hh-GLI signaling has now been implicated in
several human cancers, and targeting Hh has demonstrated
success most notably in advanced basal cell tumors and
medulloblastoma [29,30]. The majority of studies to date that
have aimed to inhibit Hh signaling have focused on inhibition of
SMO with cyclopamine or small molecule inhibitors [31]. While
this approach has demonstrated success in tumors with aberrant
canonical PTCH1 or SMO signaling, it has now become evident
that non-canonical Hh-GLI signaling may contribute to the
biology of some tumors and may be independent of SMO
signaling [32]. Therefore, targeting GLI could present an
attractive approach for the treatment of OSA since this approach
Inhibition of GLI in Canine Osteosarcoma Cells
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would be expected to inhibit contributions of both canonical and
non-canonical Hh signaling.
While several studies have demonstrated an important role for
Hh-GLI signaling in human OSA, there is little known about the
role of this pathway in canine OSA. However, at least two studies
implicate aberrant Hh signaling may be present in canine OSA
[24,25]. Interestingly, expression profiling in canine OSA patient
samples indicated that down-regulation of Hh signaling pathways
associated with poor outcome [24]. Specifically, those investigators
found that significant down-regulation of gene expression for
SMO, PTCH2, and desert hedgehog appeared to be associated with a
shortened disease free interval in dogs with OSA. GLI2 expression
was not specifically identified as being aberrant in that study,
however, GLI2 expression has been correlated with poor outcome
in human OSA patients and appears to be the primary mediator of
Hh signaling in human OSA [7,16]. The authors are not aware of
any studies previously examining expression of GLI2 in canine
OSA.
Initial experiments demonstrated high constitutive expression of
GLI1 in 2 out of 3 cell lines of canine OSA compared to canine
osteoblast cells. High fold expression of GLI1 seemed indicative
that GLI signaling was active and could contribute to osteo-
oncogenenesis. We also observed high fold expression of GLI2 in
the same two cell lines (Abrams and D17). However, GLI1 showed
10–15 times higher fold mRNA expression compared to GLI2
mRNA in canine Abrams and D17 OSA cell lines. This suggested
that GLI1 might possibly be the major Hh-GLI signaling
regulatory transcription factor in Canine OSA. While previous
studies have identified GLI1 as the main transcription factor of
Hh-GLI signaling pathway in several tumor systems, two
Figure 1. Constitutive GLI activity in canine osteosarcoma cell lines. Relative transcript expression of canine osteosarcoma cell lines and
canine osteoblast cells were determined by Real Time RT-PCR. (A) Abrams and D17 cell lines showed high relative expression of GLI1 compared to
canine osteoblasts, whereas expression in the Moresco cell line was significantly decreased. (B) The D17 cell line showed high expression of GLI2
mRNA, whereas Moresco cells expressed a significantly lower level of transcript compared to canine osteoblast cells. (C) Abrams and D17 cell lines
showed high expression of PTCH1 mRNA compared to canine osteoblast cells whereas Moresco cells had significantly lower expression. (D) Both
Abrams and D17 cell lines showed high expression of PAX6mRNA compare to canine osteoblast cells. All mRNA expressions studies were equilibrated
with the HPRT housekeeping gene. Errors bars represent S.D., statistical analysis was performed using one-way ANOVA with post-hoc Tukey’s test.
Significance denoted as: * p,0.05, * * p,0.01, * * * p,0.001.
doi:10.1371/journal.pone.0096593.g001
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independent studies have concluded that GLI2 appears to be of
highest relative importance in human OSA [7]. GANT61 is
known to inhibit both GLI1 and GLI2 transcription factors [19],
hence, additional studies would be required to determine the
contributions of individual GLI family members in canine OSA.
We found that GANT61 was capable of inhibiting cell
proliferation in all three canine cell lines but was most effective
inhibiting the growth of D17 cells that expressed highest levels of
GLI. Importantly, the IC50 value of GANT61 (based on reporter
activity) is in the range of 5 mM [19]. Results of clonogenic assays
indicated reduction in colony formation for both Abrams and D17
between 4–8 mM, whereas Moresco cells were more resistant. This
same concentration range inhibited the viability of D17 cells as
measured using MTS assays, however, Abrams and Moresco cells
required greater than 10 mM to significantly inhibit cell viability.
This discrepancy could be indicative of a differential role for GLI
in colony formation/survival vs. proliferation of canine OSA.
Alternatively, GANT61 inhibition of Abrams and D17 at
concentrations above 10 mM on MTS assay could possibly
represent off-target effects.
To further examine the effects of GANT61 on canine OSA
cells, we went on to examine expression of downstream target
genes before and after treatment with GANT61. The majority of
studies investigating downstream target genes of GLI have focused
on genes with known binding of the GLI1 consensus sequences
within the promoter region. Therefore, we chose to first examine
expression of constitutive GLI1 downstream target genes PTCH1
and PAX6, in canine OSA cells. We then went on to determine
the effect of GANT61 on the expression of these same target
genes. High expression of PTCH1 in Abrams and D17 cell lines
initially supported the notion that GLI signaling was active in
canine OSA. However, the Moresco OSA cell line showed low
expression of PTCH1 compared to osteoblast cells and this
Figure 2. Constitutive expression of GLI proteins in canine OSA
cell lines. Western Blot analyses demonstrating variable protein
expression of GLI1 and GLI2 in canine OSA cell lines. Actin served as
the internal loading control.
doi:10.1371/journal.pone.0096593.g002
Figure 3. Inhibitory effects of the GLI-inhibitor GANT61 on the colony formation and viability of canine osteosarcoma cell lines.
Canine OSA cell lines were treated with five different concentrations of the GLI-inhibitor GANT61. GANT61 decreased colony formation in (A) Abrams,
(B) D17, and (C) Moresco cell lines. (D) GANT61 also reduced cell viability, as determined by MTS assay, in all cell lines. D17 cells appeared most
sensitive to the effects of GANT61. Errors bars represent S.D.
doi:10.1371/journal.pone.0096593.g003
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correlated with low expression of GLI1 and GLI2 expression in
these cells. Importantly, PTCH1 expression was significantly
reduced in D17 cells after treatment with GANT61, supporting
the notion that PTCH1 mRNA can be regulated by the Hh-GLI
pathway in canine OSA cells. These results are in agreement with
previous studies showing that GLI1 knockdown decreases PTCH1
expression in human medulloblastoma and glioblastoma cells [26].
We also found that PAX6, one of the putative Hh/-GLI
signaling downstream target genes, showed high expression in
Abrams and D17 canine OSA cell lines as would be expected from
GLI1, GLI2, and PTCH1 expression analyses. GANT61 treatment
reduced 40% of the PAX6 expression in canine OSA cells which is
in agreement with a previous study wherein GLI1 knockdown
reduced the expression of PAX6 in human medulloblastoma [26].
It is important to note that medulloblastoma samples showed high
expression of PAX6 [33] and it is well known that medulloblas-
toma is commonly associated with activation/mutation of Hh
signaling pathway factors [34,35]. Taken together, our findings
indicate that GLI signaling may upregulate PAX6 in canine OSA.
Examination of PAX6 expression in osteocytes suggests that PAX6
regulates sclerostin, an osteocyte marker that inhibits canonical
Wnt signaling antagonist [36]. While PAX6 is one of the critical
Figure 4. Expression of GLI1 target genes after GANT61 treatments in canine D17 cells. Canine D17 OSA cells were treated with 12 mM of
GANT61 for 96 hrs and relative expression was determined by Real Time RT-PCR. (A–C) GANT61 significantly decreased expression of GLI1, GLI2, and
PTCH1mRNA compared to untreated (UT) and vehicle DMSO treated cells. (D) Treatment of D17 cells with GANT61 significantly decreased expression
of PAX6 mRNA. All mRNA expression studies were equilibrated with the housekeeping gene HPRT. Errors bars represent S.D., statistical analysis was
performed using one-way ANOVA with post-hoc Tukey’s test and significant values denoted as: * p,0.05, * * p,0.01, * * * p,0.001.
doi:10.1371/journal.pone.0096593.g004
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transcription factors that regulate several genes of cell proliferation
and cell patterning and migration of neuroectodermal precursor
cells [37,38], to the best of our knowledge, the role of PAX6 has
not been specifically examined in OSA. Notably, it has also been
reported that the PAX6 gene can possess both proto-oncogenic and
tumor suppressor characteristics and these may vary among tumor
types [26]. Our result suggests PAX6 may be acting as a proto-
oncogene in canine OSA, however, this remains speculative and
further investigation would be needed to determine the role of
PAX6 in human or canine OSA.
Altogether, the results of our studies demonstrate that 1) GLI
signaling is present in canine OSA cell lines, 2) GANT61 is
capable of altering expression of GLI target genes in canine OSA
cells, and 3) inhibition of GLI is capable of reducing proliferation
of canine OSA cells. While these findings indicate that Hh-GLI
signaling is quite similar between canine and human OSA, several
questions remain unanswered. Specifically, our studies have not
examined the individual contribution of GLI proteins in canine
OSA, whereas, GLI2 appears to be the major driver of Hh/-GLI
signaling in human OSA [7,16]. Furthermore, while the goal of
these experiments was limited to determining the presence and
function of GLI signaling, we did not investigate the specific effects
of inhibiting Hh SMO signaling upstream of GLI. Lastly, we can
make no conclusions about the clinical relevance or importance of
Hh-GLI signaling in canine OSA at this time. However, our data
supports the notion that canine OSA may serve as a model to
explore the effects of GLI inhibition and further indicates that
OSA response to Hh/-GLI inhibitors may be dependent on GLI
expression. Studies are ongoing to determine the individual
contributions of GLI transcription factors and to examine the
expression of these proteins in canine patient tumors.
Materials and Methods
GLI Inhibitor
GANT61 (Catalogue #373401) was purchased from Calbio-
chem and dissolved in DMSO at a stock concentration of 5 mg/
ml.
Cell Cultures
Canine osteoblast cells (Cn406-05) were purchased from Cell
Application Inc. Abrams and Moresco cell lines were gifts from
Dr. Douglas Thamm, Department of Clinical Sciences College of
Veterinary Medicine and Biomedical Sciences Colorado State
University [39,40]. D-17 (CCL-183) cell line was purchased from
American Type Culture Collection (ATCC). Canine OSA cell
lines were cultured at 37uC in DMEM medium (Gibco)
supplemented with 10%FBS, 1% penicillin/streptomycin (Gibco),
Figure 5. Protein expression of Hh target genes after GANT61
treatments in canine D17 cells. Canine D17 OSA cells were treated
with 20 mM of GANT61 for 96 hrs and expression was determined by
Western Blot analysis. GANT61 significantly decreased expression of
GLI1, GLI2, PTCH1, and PAX6 compared to vehicle DMSO treated cells.
Actin served as the internal loading control.
doi:10.1371/journal.pone.0096593.g005
Figure 6. Comparative transcript expression of GLI1 and GLI2 in
canine Moresco OSA cells after GANT61 treatment. (A–B) Canine
Moresco OSA cells were treated with 12 mM of GANT61 for 96 hrs and
expression levels of GLI1 and GLI2 were determined by Real Time RT-
PCR. GANT61 significantly inhibited expression of GLI1 and GLI2 mRNA
compared to untreated (UT) or vehicle DMSO treated cells. Errors bars
represent S.D., statistical analysis was performed using one-way ANOVA
and post-hoc Tukey’s test and significance denoted as: * p,0.05, * * p,
0.01, * * * p,0.001.
doi:10.1371/journal.pone.0096593.g006
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1% MEM non-essential amino acid (cellgro) and 1% MEM
vitamins (Gibco) in 5% humidified CO2 chamber. All cell lines
tested and confirmed free from mycoplasma. Canine osteoblast
cells were grown in growth medium (Cn417D-500) purchased
from Cell Application Inc. under identical conditions.
MTS Assay (Cell Proliferation Assay)
Canine OSA cell lines Abrams, D17 and Moresco were plated
in triplicate at a density of 700 cells per well in 96-well plates. After
24 hours, culture medium was replaced with fresh 2% FBS
medium containing various concentrations of GANT61 at
concentrations between 0–20 mM for 4 days. Cell viability was
measured by incubation with the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium, inner
salt (MTS) one –solution assay reagent (CellTiter 96*, Promega)
at 37uC for 1 h before reading absorbance on a spectrophotometer
(SpectraMax 190, Molecular Devices) at 490 nm. DMSO was
used as a vehicle to dissolve GANT61 and for controls.
Clonogenic Assay
Cell survival was determined by clonogenic assay based on
previous publication [41]. Cells were plated onto 6-well plate
(2000 cells/well) allowed to adhere overnight and treated after
24 hrs with GANT61 at concentration of 0, 4, 8, 10, 15, and
20 mM and incubated for 7 days. On day 7, the colonies were
washed with PBS, fixed in 100% ethanol and stained with crystal
violet solution.
Quantitative Real Time RT-PCR analysis (qRT-PCR)
Total RNA was extracted from Canine osteoblast cell line (CO),
Abrams, D17 and Moresco cell lines with Tri Regent (Sigma) and
chloroform-ethanol method. Then determined the quantity and
quality of RNA with the help of Biophotometer (eppendorf). Total
2 mg of total RNA was converted to cDNA by using High
Capacity RNA to cDNA Kit (Applied Biosystem). Transcript
expression (mRNA) level of GLI1, GLI2, PTCH1, and PAX6 was
determined by using the StepOne Plus Real-Time PCR system
(Applied Biosystem). Taq-Man assays (Applied Biosystem) GLI1
(Assay ID# Cf04230663_m1) GLI2 (Assay ID#4331348), PTCH1
(Assay ID #Cf02690587_m1), and PAX6 (Assay
ID#Cf02675240_m1) were used to determine the expression.
All transcripts expression was equilibrated with endogenous
control HPRT1 (Assay ID#Cf02626256_m1) expression (Figure
S1, S2, S3). The real time expression calculation is based on Delta-
delta (DDC) method by PE Applied Biosystem (Perkin Elmer,
Forster City, CA)[42].
Western blot analysis
The D17 cell line was treated with 20 mM GANT61 or vehicle
DMSO for 96 hrs and cell lysate was made in lysis buffer. Protein
was quantified using a BCA protein Assay Reagent (bicinchonic
acid) (Pierce). A total of 40 mg of protein was loaded per sample in
the 7.5% polyacrylamide gels under denaturing and reducing
conditions and protein was transferred to nitrocellulose mem-
branes. After transfer of protein, the membrane was probed and
incubated overnight at 4uC with antibodies Rabbit anti-GLI1
(Abcam ab49314), Rabbit anti-GLI2 (Abcam ab26056), Rabbit
anti-Patch1(Sigma-Aldrich P0088), Rabbit anti-Pax6 (Abcam
ab5790), and Mouse anti-Actin (Santa Cruz sc-56459) in 5%
non-fat milk. Then membranes were washed and subsequently
exposed to the appropriate HRP-conjugated secondary antibodies
for 1 hr. at room temperature. Bands were visualized by the
enhanced chemiluminescence (Pierce) in Fluorchem E Imaging
system (Protein Simple, CA). Constitutive expression levels of
GLI1 and GLI2 were performed similarly, in the absence of
treatment for Abrams, D17 and Moresco cell lines.
Statistical analysis
All results shown are representative of experiments done in
triplicate. Analyses were performed using one-way ANOVA and
post-doc Tukey’s testing (GraphPad Prism version 5.0). Differenc-
es were considered significant with a p,0.05.
Supporting Information
Figure S1 Amplification plot of GLI1, GLI2, PTCH1 and
PAX6 RNA expression in canine OSA cell lines: This plot
was used to determine the Cycle threshold (Ct)value;
PCR Cycle number as X and the mean DRn (an
algorithm compared the amount of the TaqMan assay
reporter dye emission (R) with the quenching dye
emission (Q) during the Real Time PCR amplification
process) value as Y. The standard DRn (Y=0.05) of
exponential phase of amplification was selected to determine the
optimal CT value. Less cycle number to reach exponential phase
of amplification indicates high copy number of RNA (less Ct
value). (A) Amplification plot of GLI1 in Canine osteoblast (CO),
Moresco, Abrams and D17. (B) Amplification plot of GLI2 in
Canine osteoblast (CO), Moresco, Abrams and D17. (C)
Amplification plot of PTCH1 in canine CO, Moresco, Abrams
and D17. (D) Amplification plot of PAX6 in canine CO, Moresco,
Abrams and D17.
(TIF)
Figure S2 Amplification plot of GLI1, GLI2, PTCH1 and
PAX6 mRNA expression in canine cell line D17 after the
treatment of GANT61 and DMSO. (A) Amplification plot of
GLI1 expression in Canine OSA D17 cell line compared to
GANT61 and DMSO (control). (B) Amplification plot of GLI2
expression in D17 cell line compared to GANT61 and DMSO
(control). (C) Amplification plot of PTCH1 in canine OSA cell line
D17 compared to GANT61 and DMSO treatment. (D) Ampli-
fication plot of PAX6 in canine OSA cell line D17 compared to
GANT61 and DMSO treatment. GANT61 treated cells showed
increased number of cycle to reach exponential phase of
amplification compare to DMSO (control) (decreased mRNA
copy number in GANT61 treated cells compared to DMSO).
(TIF)
Figure S3 Amplification plot of GLI1 and GLI2 mRNA
expression in canine cell line Moresco after the treat-
ment of GANT61 and DMSO. (A) Amplification plot of GLI1
expression in Canine OSA Moresco cell line after the treatment
GANT61 and DMSO (control). (B) Amplification plot of GLI2
expression in Canine OSA Moresco cell line after the treatment of
GANT61 and DMSO (control). GANT61 treated cells showed
increased number of cycle to reach exponential phase of
amplification compare to DMSO (control) (decreased mRNA
copy number in GANT61 treated cells compared to DMSO).
(TIF)
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